Deficient mismatch repair as a prognostic marker in stage II colon cancer patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F19%3AN0000039" target="_blank" >RIV/00064173:_____/19:N0000039 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11140/19:10399725 RIV/00669806:_____/19:10399725 RIV/00209805:_____/19:00078312

Výsledek na webu

<a href="https://doi.org/10.1016/j.ejso.2019.05.023" target="_blank" >https://doi.org/10.1016/j.ejso.2019.05.023</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.ejso.2019.05.023" target="_blank" >10.1016/j.ejso.2019.05.023</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Deficient mismatch repair as a prognostic marker in stage II colon cancer patients

Popis výsledku v původním jazyce

BACKGROUND: A number of reports have evaluated the relationship between deficient DNA mismatch repair (dMMR) and colorectal cancer prognosis. Unfortunately, the exact prognostic role of dMMR has not been clearly established due to contradictory results. This study aims to determine the prognostic impact of dMRR in stage II colon cancer patients only. The appropriate identification of high-risk stage II colon cancers is of paramount importance in the selection of patients who may benefit from adjuvant treatment after surgery. METHODS: Four hundred and fifty-two patients with curative resection of stage II colon cancer were included. Hospital records were used as data source, providing clinical, surgical, pathology, oncology and follow-up information for statistical analysis focusing on overall survival (OS) and time to progression (TTP). Mismatch repair status was determined by immunohistochemistry. Patient survival was followed-up for a mean of 77.35 months. RESULTS: dMMR was detected in 93 of 452 patients (20.6%). No impact on overall survival (Log-Rank, p = 0.583, 95% CI 0.76-1.67). However, the hazard ratio 0.50 for TTP was highly significant (Log-Rank, p = 0.012, 95% CI 0.28-0.87) in patients with dMMR compared with those with mismatch repair proficient tumours (pMMR). CONCLUSIONS: Patients with dMMR tumours have a lower risk for recurrence compared to those with pMMR tumours, but this finding did not correlate to better overall survival

Název v anglickém jazyce

Deficient mismatch repair as a prognostic marker in stage II colon cancer patients

Popis výsledku anglicky

BACKGROUND: A number of reports have evaluated the relationship between deficient DNA mismatch repair (dMMR) and colorectal cancer prognosis. Unfortunately, the exact prognostic role of dMMR has not been clearly established due to contradictory results. This study aims to determine the prognostic impact of dMRR in stage II colon cancer patients only. The appropriate identification of high-risk stage II colon cancers is of paramount importance in the selection of patients who may benefit from adjuvant treatment after surgery. METHODS: Four hundred and fifty-two patients with curative resection of stage II colon cancer were included. Hospital records were used as data source, providing clinical, surgical, pathology, oncology and follow-up information for statistical analysis focusing on overall survival (OS) and time to progression (TTP). Mismatch repair status was determined by immunohistochemistry. Patient survival was followed-up for a mean of 77.35 months. RESULTS: dMMR was detected in 93 of 452 patients (20.6%). No impact on overall survival (Log-Rank, p = 0.583, 95% CI 0.76-1.67). However, the hazard ratio 0.50 for TTP was highly significant (Log-Rank, p = 0.012, 95% CI 0.28-0.87) in patients with dMMR compared with those with mismatch repair proficient tumours (pMMR). CONCLUSIONS: Patients with dMMR tumours have a lower risk for recurrence compared to those with pMMR tumours, but this finding did not correlate to better overall survival

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Journal of Surgical Oncology

ISSN

0748-7983

e-ISSN

1532-2157

Svazek periodika

45

Číslo periodika v rámci svazku

10

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

8

Strana od-do

1854-1861

Kód UT WoS článku

000491301600016

EID výsledku v databázi Scopus

2-s2.0-85066955109